

LIMITATIONS OF THE STUDY:

1. We could cover only nine therapeutic categories so other remaining categories need to be studied upon.
2. State Food and Drug Administration agencies (FDA) do not have any compiled data of approved formulations making the task very complicated. Such database must be built by these state level regulatory agencies and the same should be uploaded on their websites.
3. Since the brand data collection was carried out using information collected from various associations, access to each data was time consuming.
4. Another hurdle in compilation of brands for both states was, the regulatory process giving the manufacturing permissions to pharmaceutical companies. A company may obtain the manufacturing license number in one state to manufacture a particular brand and then market that brand in any other state and thus that brand may be registered in the state where FDA gave a manufacturing permission but not in FDA register of state in which it is widely sold.